Foghorn Therapeutics reported a net margin of -44.77% for the quarter ended Jun 2026. These financial ratios cover 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||||||||||||||
| EBT Margin | -65,268.29% | -3,998.32% | -686.58% | -608.31% | -388.44% | -690.39% | -563.72% | -509.82% | -77.85% | -383.43% | -495.37% | -333.61% | -244.90% | -682.88% | -339.73% | -248.62% | -202.00% | -239.71% | -607.01% | -44.77% | ||||||||
| EBIT Margin | -64,051.22% | -3,938.57% | -709.29% | -650.07% | -425.97% | -762.09% | -627.56% | -572.42% | -97.73% | -441.29% | -558.30% | -386.64% | -305.48% | -840.51% | -384.96% | -279.17% | -226.92% | -258.22% | -660.33% | -54.78% | ||||||||
| EBITDA Margin | -64,051.22% | -3,938.57% | -709.29% | -650.07% | -425.97% | -762.09% | -627.56% | -572.42% | -97.73% | -441.29% | -558.30% | -386.64% | -305.48% | -840.51% | -384.96% | -279.17% | -226.92% | -258.22% | -660.33% | -54.78% | ||||||||
| Operating Margin | -64,051.22% | -3,938.57% | -709.29% | -650.07% | -425.97% | -762.09% | -627.56% | -572.42% | -97.73% | -441.29% | -558.30% | -386.64% | -305.48% | -840.51% | -384.96% | -279.17% | -226.92% | -258.22% | -660.33% | -54.78% | ||||||||
| Net Margin | -65,268.29% | -3,998.32% | -686.58% | -608.31% | -388.44% | -690.39% | -574.27% | -526.65% | -82.07% | -417.85% | -495.37% | -333.61% | -244.90% | -682.88% | -339.73% | -248.62% | -202.00% | -239.71% | -607.01% | -44.77% | ||||||||
| FCF Margin | -50,565.85% | 1,655.26% | 6,920.59% | -654.25% | -306.24% | -697.73% | -599.28% | -583.03% | -156.15% | -478.04% | -583.09% | -370.99% | -272.98% | -875.28% | -403.16% | -278.18% | -231.33% | -240.85% | -774.44% | -111.12% | ||||||||
| Efficiency | ||||||||||||||||||||||||||||
| Assets AverageAssets Avg. | 197.30M | 352.92M | 504.04M | 472.60M | 445.42M | 419.41M | 388.88M | 356.23M | 326.50M | 299.67M | 270.46M | 291.79M | 318.48M | 296.18M | 271.34M | 242.46M | 215.60M | 201.53M | 210.13M | 212.78M | ||||||||
| Invested CapitalInvested Cap. | 100.90M | 96.87M | ||||||||||||||||||||||||||
| Asset Utilization RatioAsset Util. | 0.00 | 0.00 | 0.01 | 0.02 | 0.04 | 0.05 | 0.05 | 0.06 | 0.10 | 0.11 | 0.13 | 0.12 | 0.08 | 0.08 | 0.09 | 0.10 | 0.11 | 0.15 | 0.13 | 0.17 | ||||||||
| Leverage & Solvency | ||||||||||||||||||||||||||||
| Interest Coverage RatioInterest Cover | -52.63 | -65.92 | ||||||||||||||||||||||||||
| Debt Ratio | 0.11 | |||||||||||||||||||||||||||
| Times Interest Earned | -52.63 | -65.92 | ||||||||||||||||||||||||||
| Valuation | ||||||||||||||||||||||||||||
| Price to EarningsP/E | -19.28 | -33.13 | -23.44 | -20.73 | -13.92 | -9.23 | -8.51 | -9.99 | -14.71 | -11.31 | -11.42 | -13.84 | -27.07 | -13.45 | -10.06 | -13.96 | -16.79 | -13.80 | -14.15 | -39.82 | ||||||||
| Price to SalesP/S | 0.01M | 0.00M | 160.96 | 126.09 | 54.06 | 63.74 | 48.84 | 52.62 | 12.08 | 47.27 | 56.58 | 46.19 | 66.29 | 91.88 | 34.17 | 34.71 | 33.91 | 33.09 | 85.90 | 17.83 | ||||||||
| Price to BookP/B | 6.37 | 9.75 | 8.71 | 11.89 | 14.74 | 0.00M | -10.55 | -5.97 | -3.68 | -3.53 | -2.93 | -22.21 | -18.30 | -5.76 | -3.30 | -3.42 | -3.08 | -2.82 | -3.67 | -3.54 | ||||||||
| Enterprise Value | 458.19M | 843.39M | 417.33M | 504.93M | 271.01M | 214.49M | 208.67M | 236.94M | 140.78M | 192.38M | 206.50M | 179.19M | 459.89M | 206.95M | 142.36M | 188.45M | 185.91M | 223.82M | 191.72M | 218.45M | ||||||||
| EV to EBIT | -17.45 | -30.03 | -15.01 | -17.30 | -9.59 | -6.73 | -6.26 | -7.39 | -8.24 | -7.56 | -7.32 | -6.73 | -19.28 | -8.62 | -6.21 | -8.93 | -10.05 | -9.37 | -8.89 | -24.81 | ||||||||
| EV to EBITDA | -17.45 | -30.03 | -15.01 | -17.30 | -9.59 | -6.73 | -6.26 | -7.39 | -8.24 | -7.56 | -7.32 | -6.73 | -19.28 | -8.62 | -6.21 | -8.93 | -10.05 | -9.37 | -8.89 | -24.81 | ||||||||
| Market Capitalization | 516.03M | 944.52M | 630.97M | 566.14M | 358.64M | 266.71M | 259.31M | 294.64M | 211.09M | 272.72M | 285.75M | 318.14M | 517.57M | 262.40M | 203.38M | 262.28M | 276.49M | 305.95M | 280.64M | 286.53M | ||||||||
| Price to FCFP/FCF | -24.89 | 80.03 | 2.33 | -19.27 | -17.65 | -9.14 | -8.15 | -9.03 | -7.73 | -9.89 | -9.70 | -12.45 | -24.28 | -10.50 | -8.48 | -12.48 | -14.66 | -13.74 | -11.09 | -16.04 | ||||||||
| EV to FCF | -22.10 | 71.46 | 1.54 | -17.19 | -13.34 | -7.35 | -6.56 | -7.26 | -5.16 | -6.98 | -7.01 | -7.01 | -21.58 | -8.28 | -5.93 | -8.96 | -9.86 | -10.05 | -7.58 | -12.23 | ||||||||
| EV to CFO | -22.35 | 70.98 | 1.54 | -17.40 | -13.56 | -7.42 | -6.69 | -7.36 | -5.17 | -6.99 | -7.04 | -7.02 | -21.89 | -8.44 | -5.94 | -8.97 | -9.86 | -10.05 | -7.59 | -12.24 | ||||||||
| Return Ratios | ||||||||||||||||||||||||||||
| Return on Sales [ROS]ROS | -64,051.22% | -3,938.57% | -709.29% | -650.07% | -425.97% | -762.09% | -627.56% | -572.42% | -97.73% | -441.29% | -558.30% | -386.64% | -305.48% | -840.51% | -384.96% | -279.17% | -226.92% | -258.22% | -660.33% | -54.78% | ||||||||
| Return on Capital Employed [ROCE]ROCE | -52.49% | -33.11% | -23.13% | -26.22% | -29.04% | -32.16% | -36.82% | -41.89% | -41.65% | -44.73% | -47.06% | -40.41% | -39.80% | -44.80% | -48.69% | -55.79% | -66.29% | -60.93% | -58.36% | -44.86% | ||||||||
| Return on Assets [ROA]ROA | -48.27% | -29.08% | -21.02% | -23.17% | -24.36% | -25.96% | -28.92% | -32.18% | -31.61% | -32.84% | -34.37% | -29.63% | -28.64% | -29.25% | -30.16% | -32.02% | -34.78% | -38.53% | -36.76% | -30.86% |